288 related articles for article (PubMed ID: 38465614)
1. A pivotal decade for bispecific antibodies?
Surowka M; Klein C
MAbs; 2024; 16(1):2321635. PubMed ID: 38465614
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
Li X; Zhang P; Sun H; Han L; Jiang Z; Yu J
Expert Opin Biol Ther; 2023; 23(12):1193-1195. PubMed ID: 37852928
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibodies: design, therapy, perspectives.
Sedykh SE; Prinz VV; Buneva VN; Nevinsky GA
Drug Des Devel Ther; 2018; 12():195-208. PubMed ID: 29403265
[TBL] [Abstract][Full Text] [Related]
4. Opportunities and challenges of bi-specific antibodies.
Segués A; Huang S; Sijts A; Berraondo P; Zaiss DM
Int Rev Cell Mol Biol; 2022; 369():45-70. PubMed ID: 35777864
[TBL] [Abstract][Full Text] [Related]
5. The present and future of bispecific antibodies for cancer therapy.
Klein C; Brinkmann U; Reichert JM; Kontermann RE
Nat Rev Drug Discov; 2024 Apr; 23(4):301-319. PubMed ID: 38448606
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to watch in 2023.
Kaplon H; Crescioli S; Chenoweth A; Visweswaraiah J; Reichert JM
MAbs; 2023; 15(1):2153410. PubMed ID: 36472472
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
8. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
Liu X; Zhao J; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibodies for cancer therapy: A review.
Krishnamurthy A; Jimeno A
Pharmacol Ther; 2018 May; 185():122-134. PubMed ID: 29269044
[TBL] [Abstract][Full Text] [Related]
10. Update on bi-specific monoclonal antibodies for blood cancers.
Shouse G
Curr Opin Oncol; 2023 Sep; 35(5):441-445. PubMed ID: 37551951
[TBL] [Abstract][Full Text] [Related]
11. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.
Dong J; Sereno A; Snyder WB; Miller BR; Tamraz S; Doern A; Favis M; Wu X; Tran H; Langley E; Joseph I; Boccia A; Kelly R; Wortham K; Wang Q; Berquist L; Huang F; Gao SX; Zhang Y; Lugovskoy A; Martin S; Gouvis H; Berkowitz S; Chiang G; Reff M; Glaser SM; Hariharan K; Demarest SJ
J Biol Chem; 2011 Feb; 286(6):4703-17. PubMed ID: 21123183
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
Zhang T; Lin Y; Gao Q
Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
[TBL] [Abstract][Full Text] [Related]
13. Bispecific antibodies in haematological malignancies.
Viardot A; Bargou R
Cancer Treat Rev; 2018 Apr; 65():87-95. PubMed ID: 29635163
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibody based therapeutics: Strengths and challenges.
Thakur A; Huang M; Lum LG
Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.
Huang S; van Duijnhoven SMJ; Sijts AJAM; van Elsas A
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3111-3122. PubMed ID: 32989604
[TBL] [Abstract][Full Text] [Related]
17. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
[TBL] [Abstract][Full Text] [Related]
18. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
Long M; Mims AS; Li Z
Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
[TBL] [Abstract][Full Text] [Related]
19. Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow.
Ahamadi-Fesharaki R; Fateh A; Vaziri F; Solgi G; Siadat SD; Mahboudi F; Rahimi-Jamnani F
Mol Ther Oncolytics; 2019 Sep; 14():38-56. PubMed ID: 31011631
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
